Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Work In Process for 9 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process rose 22.73% to $27.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.0 million, a 22.73% increase, with the full-year FY2025 number at $27.0 million, up 22.73% from a year prior.
  • Work In Process was $27.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $29.2 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $29.2 million in Q3 2025 to a low of $6.8 million in Q1 2021.
  • A 5-year average of $17.9 million and a median of $18.7 million in 2023 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: soared 76.75% in 2022, then dropped 21.77% in 2025.
  • Ultragenyx Pharmaceutical's Work In Process stood at $10.5 million in 2021, then surged by 66.47% to $17.5 million in 2022, then rose by 7.85% to $18.9 million in 2023, then increased by 16.66% to $22.0 million in 2024, then rose by 22.73% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Work In Process are $27.0 million (Q4 2025), $29.2 million (Q3 2025), and $19.8 million (Q2 2025).